Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
Price : $35 *
At a glance
- Drugs KD 018 (Primary) ; Capecitabine
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jan 2019 Planned End Date changed from 1 Jul 2018 to 1 Mar 2020.
- 18 Jan 2019 Planned primary completion date changed from 1 Jan 2018 to 1 Sep 2019.
- 18 Jan 2019 Status changed from recruiting to active, no longer recruiting.